表紙:仮想臨床試験の市場規模・市場シェア・市場動向の分析 (2022-2030年):試験設計 (介入型・観察型・拡張アクセス)・適応症 (腫瘍・心臓血管)・地域別
市場調査レポート
商品コード
1046680

仮想臨床試験の市場規模・市場シェア・市場動向の分析 (2022-2030年):試験設計 (介入型・観察型・拡張アクセス)・適応症 (腫瘍・心臓血管)・地域別

Virtual Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Indication (Oncology, Cardiovascular), By Region, And Segment Forecasts, 2022 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
仮想臨床試験の市場規模・市場シェア・市場動向の分析 (2022-2030年):試験設計 (介入型・観察型・拡張アクセス)・適応症 (腫瘍・心臓血管)・地域別
出版日: 2022年01月12日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の仮想臨床試験の市場規模は予測期間中5.7%のCAGRで推移し、2030年には129億米ドルの規模に成長すると予測されています。

新型コロナウイルス感染症 (COVID-19) の世界的流行が同市場に大きな影響を与えています。

臨床試験におけるデータ収集の強化に伴う患者の多様性に対するニーズの高まりも市場の成長を後押ししています。

当レポートでは、世界の仮想臨床試験の市場を調査し、市場の定義と概要、市場影響因子の分析、市場規模の推移・予測、試験設計・適応症・地域/主要国など各種区分別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 仮想/分散型臨床試験市場の可変因子・動向・展望

  • 市場系統の見通し
  • 普及・成長の見通しマッピング
  • COVID-19の影響
  • 市場力学
  • 市場分析ツール

第4章 仮想/分散型臨床試験市場:試験設計別

  • ダッシュボード
  • 市場シェア分析
  • 世界の仮想/分散型臨床試験市場:試験設計別
  • 市場規模の予測・動向分析
    • 介入型
    • 観察型
    • 拡張アクセス

第5章 仮想/分散型臨床試験市場:適応症別

  • ダッシュボード
  • 市場シェア分析
  • 世界の仮想/分散型臨床試験市場:癌タイプ別
  • 市場規模の予測・動向分析
    • 腫瘍
    • 心臓血管
    • その他

第6章 仮想/分散型臨床試験市場:地域・試験設計別

  • 地域市場ダッシュボード
  • 地域市場シェア分析
  • 市場規模の予測・動向分析
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第7章 仮想/分散型臨床試験市場:競合分析

  • 主要企業のプロファイル
    • ICON, plc
    • PAREXEL International Corporation
    • IQVIA
    • Covance
    • PRA Health Sciences
    • LEO Innovation Lab
    • Medidata
    • Oracle
    • CRF Health
    • Clinical Ink
    • Medable Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Virtual/Decentralized Clinical Trials Market, By Region, 2017 - 2030 (USD Million)
  • Table 4 Global Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 5 Global Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 6 North America Virtual/Decentralized Clinical Trials Market, By Country, 2017 - 2030 (USD Million)
  • Table 7 North America Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 8 North America Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 9 U.S. Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 10 U.S. Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 11 Canada Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 12 Canada Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 13 Europe Virtual/Decentralized Clinical Trials Market, By Country, 2017 - 2030 (USD Million)
  • Table 14 Europe Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 15 Europe Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 16 U.K. Virtual Clinical/Decentralized Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 17 U.K. Virtual Clinical/Decentralized Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 18 Germany Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 19 Germany Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 20 France Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 21 France Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 22 Italy Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 23 Italy Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 24 Spain Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 25 Spain Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 26 Asia Pacific Virtual/Decentralized Clinical Trials Market, By Country, 2017 - 2030 (USD Million)
  • Table 27 Asia Pacific Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 28 Asia Pacific Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 29 India Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 30 India Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 31 Japan Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 32 Japan Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 33 China Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 34 China Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 35 Australia Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 36 Australia Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 37 South Korea Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 38 South Korea Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 39 Latin America Virtual/Decentralized Clinical Trials Market, By Country, 2017 - 2030 (USD Million)
  • Table 40 Latin America Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 41 Latin America Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 42 Brazil Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 43 Brazil Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 44 Mexico Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 45 Mexico Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 46 Argentina Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 47 Argentina Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 48 Colombia Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 49 Colombia Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 50 MEA Virtual/Decentralized Clinical Trials Market, By Country, 2017 - 2030 (USD Million)
  • Table 51 MEA Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 52 MEA Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 53 South Africa Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 54 South Africa Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 55 Saudi Arabia Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 56 Saudi Arabia Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)
  • Table 57 UAE Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 - 2030 (USD Million)
  • Table 58 UAE Virtual/Decentralized Clinical Trials Market, By Indication, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Virtual/decentralized clinical trials market: Market snapshot
  • Fig. 9 Virtual/decentralized clinical trials market: Market segmentation
  • Fig. 10 Virtual/decentralized clinical trials market strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Virtual/decentralized clinical trials market driver impact
  • Fig. 14 Virtual/decentralized clinical trials market restraint impact
  • Fig. 15 Virtual/decentralized clinical trials market porter's five forces analysis
  • Fig. 16 Virtual/decentralized clinical trials market PESTEL analysis
  • Fig. 17 Virtual/decentralized clinical trials market: study design segment dashboard
  • Fig. 18 Virtual/decentralized clinical trials market: Study design movement analysis
  • Fig. 19 Interventional market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 20 Observational market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 21 Expanded Access market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 22 Virtual/decentralized clinical trials market: Segment dashboard
  • Fig. 23 Virtual/decentralized clinical trials market: Indication movement analysis
  • Fig. 24 virtual/decentralized market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 25 Cardiovascular market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 27 Global virtual/decentralized clinical trials market: Regional movement analysis
  • Fig. 28 Global virtual/decentralized clinical trials market: Regional outlook and key takeaways
  • Fig. 29 North America market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 30 U.S. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 31 Canada market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 32 Europe market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 33 U.K. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 34 Germany market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 35 France market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 36 Italy market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 37 Spain market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 38 Asia Pacific market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 40 Japan market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 41 China market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 42 Australia market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 43 South Korea market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 44 Latin America market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 45 Brazil market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 46 Mexico market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 47 Argentina market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 48 Colombia market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 50 South Africa market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 52 UAE market estimates and forecast, 2017 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-239-7

Virtual Clinical Trials Market Growth & Trends:

The global virtual clinical trials market size is expected to reach USD 12.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2022 to 2030. The COVID-19 pandemic has significantly impacted the market. The growing need for patient diversity clubbed with enhanced data collection in clinical trials is boosting the market growth.

There has been a rise in the R&D of new drugs and vaccines that has increased the volume and complexity of clinical trials. Virtual clinical trials eliminate challenges posed by traditional clinical trials for example delays in patient recruitment and time-consuming procedures. Also, studies have revealed that around 75.0% of people favored a mobile trial over traditional ones and 80.0% of patients are more likely to participate in a clinical trial that uses mobile technology.

The market is recovering at a significant pace after the pandemic as it offers various benefits to patients as well as sponsors. During the pandemic, traveling was potentially dangerous. It can be expensive, even incurring lost wages or requiring that childcare/eldercare be hired. These drawbacks limit initial interest and provide a simple solution for virtual clinical trials. Virtual clinical trials offer various benefits such as effective data collection, analysis, and monitoring large amounts of data in real-time.

Virtual trials make use of monitoring devices, software apps, online social engagement platforms to conduct every step of the clinical trial process including patient recruitment, counseling, measuring clinical endpoints, informed consent, and adverse reactions. Telehealth, home care, and remote patient monitoring has been gaining momentum as a healthcare offering, and the COVID-19 is adding more horsepower to this initiative.

Virtual Clinical Trials Market Report Highlights:

  • The oncology segment held 25.2% of the revenue share in 2021. The increasing adoption of virtual trials especially in oncology clinical research for the diverse populations is responsible for the growth of the segment
  • The interventional design segment accounted for the largest revenue share of 46.7% in 2021
  • North America held 49.2% of the revenue share in 2021. Favorable government initiatives and the presence of large numbers of players in the U.S. offerings advanced services are responsible for market growth
  • In Asia Pacific, the market is expected to witness the fastest CAGR of 6.8% over the forecast period owing to the increasing patient pool and cost-efficient services

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Study design
    • 1.1.2. Indication
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1: Understanding the market dynamics
    • 1.9.2. Objective 2: Understanding the market estimates and forecasts
    • 1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
    • 1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Virtual/Decentralized Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. COVID-19 pandemic impact on clinical trial activity
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. The growing role technology in the healthcare
      • 3.4.1.2. Benefits of virtual trials
      • 3.4.1.3. Government support
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Data Security
    • 3.4.3. Industry Challenge
  • 3.5. Virtual/Decentralized Clinical Trials: Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier Power
      • 3.5.1.2. Buyer Power
      • 3.5.1.3. Substitution Threat
      • 3.5.1.4. Threat from new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis

Chapter 4. Virtual/Decentralized Clinical Trials Market: Segment Analysis, By Study Design, 2017 - 2030 (USD Million)

  • 4.1. Segment Dashboard
  • 4.2. Study Design Market Share Analysis, 2020 & 2030
  • 4.3. Global Virtual/Decentralized Clinical Trials Market, By Study Design, 2017 to 2030
  • 4.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 4.4.1. Interventional
    • 4.4.2. Observational
    • 4.4.3. Expanded Access

Chapter 5. Virtual/Decentralized Clinical Trials Market: Segment Analysis, By Indication, 2017 - 2030 (USD Million)

  • 5.1. Segment Dashboard
  • 5.2. Indication Market Share Analysis, 2020 & 2030
  • 5.3. Global Virtual/Decentralized Clinical Trials Market, By Cancer Type, 2017 to 2030
  • 5.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 5.4.1. Oncology
    • 5.4.2. Cardiovascular
    • 5.4.3. Others

Chapter 6. Virtual/Decentralized Clinical Trials Market: Regional Market Analysis, by Study Design, 2017 - 2030 (USD Million)

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2020 & 2030
  • 6.3. Market Size, & Forecasts, and Trend Analysis, 2017 to 2030:
  • 6.4. North America
    • 6.4.1. Market estimates and forecast, by country, 2017 - 2030 (USD Million)
    • 6.4.2. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
    • 6.4.3. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.4.4. U.S.
      • 6.4.4.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.4.4.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.4.5. Canada
      • 6.4.5.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.4.5.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Market estimates and forecast, by country, 2017 - 2030 (USD Million)
    • 6.5.2. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
    • 6.5.3. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.5.4. Germany
      • 6.5.4.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.5.4.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.5.5. U.K.
      • 6.5.5.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.5.5.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.5.6. France
      • 6.5.6.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.5.6.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.5.7. Italy
      • 6.5.7.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.5.7.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.5.8. Spain
      • 6.5.8.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.5.8.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Market estimates and forecast, by country, 2017 - 2030 (USD Million)
    • 6.6.2. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
    • 6.6.3. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.6.4.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.6.5. Japan
      • 6.6.5.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.6.5.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.6.6. China
      • 6.6.6.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.6.6.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.6.7.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.6.8. South Korea
      • 6.6.8.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.6.8.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Market estimates and forecast, by country, 2017 - 2030 (USD Million)
    • 6.7.2. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
    • 6.7.3. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.7.4. Brazil
      • 6.7.4.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.7.4.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.7.5. Mexico
      • 6.7.5.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.7.5.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.7.6. Argentina
      • 6.7.6.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.7.6.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.7.7. Colombia
      • 6.7.7.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.7.7.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Market estimates and forecast, by country, 2017 - 2030 (USD Million)
    • 6.8.2. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
    • 6.8.3. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.8.4. South Africa
      • 6.8.4.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.8.4.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.8.5. Saudi Arabia
      • 6.8.5.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.8.5.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)
    • 6.8.6. UAE
      • 6.8.6.1. Market estimates and forecast, by study design, 2017 - 2030 (USD Million)
      • 6.8.6.2. Market estimates and forecast, by indication, 2017 - 2030 (USD Million)

Chapter 7. Virtual/Decentralized Clinical Trials Market- Competitive Analysis

  • 7.1. Key companies profiled
    • 7.1.1. ICON, plc
      • 7.1.1.1. Company Overview
      • 7.1.1.2. Financial Performance
      • 7.1.1.3. Product Benchmarking
      • 7.1.1.4. Strategic Initiatives
    • 7.1.2. PAREXEL International Corporation
      • 7.1.2.1. Company Overview
      • 7.1.2.2. Financial Performance
      • 7.1.2.3. Product Benchmarking
      • 7.1.2.4. Strategic Initiatives
    • 7.1.3. IQVIA
      • 7.1.3.1. Company Overview
      • 7.1.3.2. Financial Performance
      • 7.1.3.3. Product Benchmarking
      • 7.1.3.4. Strategic Initiatives
    • 7.1.4. Covance
      • 7.1.4.1. Company Overview
      • 7.1.4.2. Financial Performance
      • 7.1.4.3. Product Benchmarking
      • 7.1.4.4. Strategic Initiatives
    • 7.1.5. PRA Health Sciences
      • 7.1.5.1. Company Overview
      • 7.1.5.2. Financial Performance
      • 7.1.5.3. Product Benchmarking
      • 7.1.5.4. Strategic Initiatives
    • 7.1.6. LEO Innovation Lab
      • 7.1.6.1. Company Overview
      • 7.1.6.2. Financial Performance
      • 7.1.6.3. Product Benchmarking
      • 7.1.6.4. Strategic Initiatives
    • 7.1.7. Medidata
      • 7.1.7.1. Company Overview
      • 7.1.7.2. Financial Performance
      • 7.1.7.3. Product Benchmarking
      • 7.1.7.4. Strategic Initiatives
    • 7.1.8. Oracle
      • 7.1.8.1. Company Overview
      • 7.1.8.2. Financial Performance
      • 7.1.8.3. Product Benchmarking
      • 7.1.8.4. Strategic Initiatives
    • 7.1.9. CRF Health
      • 7.1.9.1. Company Overview
      • 7.1.9.2. Financial Performance
      • 7.1.9.3. Product Benchmarking
      • 7.1.9.4. Strategic Initiatives
    • 7.1.10. Clinical Ink
      • 7.1.10.1. Company Overview
      • 7.1.10.2. Financial Performance
      • 7.1.10.3. Product Benchmarking
      • 7.1.10.4. Strategic Initiatives
    • 7.1.11. Medable Inc.
      • 7.1.11.1. Company Overview
      • 7.1.11.2. Financial Performance
      • 7.1.11.3. Product Benchmarking
      • 7.1.11.4. Strategic Initiatives